Effectiveness of the 2009 seasonal influenza vaccine against pandemic influenza A(H1N1)2009 in healthcare workers in New Zealand, June-August 2009

Eurosurveillance

Volumn 16, Issue 2, 2011, Pages

  Jefferies, S ^a,b   Earl, D ^b   Berry, N ^b   Blackmore, T ^b   Rooker, S ^b   Raymond, N ^b   Pritchard, A ^a   Weatherall, M ^b,c   Beasley, R ^a,b   Perrin, K ^a,b  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS RNA;

2009 H1N1 INFLUENZA; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FLU LIKE SYNDROME; HEALTH CARE PERSONNEL; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; NOSE SMEAR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEASONAL INFLUENZA; SEROTYPE; THROAT CULTURE; VIRUS DETECTION; VIRUS IDENTIFICATION;

EID: 78951473177     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. GenBank sequences from pandemic (H1N1) 2009 viruses. National Center for Biotechnology Information. [Accessed April 2010]. Available from: www.ncbi.nlm.nih.gov/genomes/FLU/SwineFlu.html
2. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25):2605-15.
3. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325(5937):197-201.
4. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361(20):1945-52.
5. Centers for Disease Control and Prevention (CDC). Serum crossreactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58(19):521-4.
6. Centers for Disease Control and Prevention (CDC). Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009. MMWR Morb Mortal Wkly Rep. 2009;58(44):1241-5.
7. Kelly H, Grant K. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 2009;14(31):pii=19288. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19288
8. Cutler J, Schleihauf E, Hatchette TF, Billard B, Watson-Creed G, Davidson R, et al. Investigation of the first cases of human-tohuman infection with the new swine-origin influenza A (H1N1) virus in Canada. CMAJ. 2009;181(3-4):159-63.
9. Garcia-Garcia L, Valdespino-Gomez JL, Lazcano-Ponce E, Jimenez-Corona A, Higuera-Iglesias A, Cruz-Hervert P, et al. Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: Case-control study in Mexico city. BMJ. 2009;339:b3928.
10. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, Grajales-Muniz C, Robles-Perez E, Gonzalez-Leon M, et al. Infection and death from influenza A/H1N1 virus in Mexico: a retrospective analysis. Lancet. 2009;374(9707):2072-9.
11. Mogabgab WJ, Leiderman E. Immunogenicity of 1967 polyvalent and 1968 Hong Kong influenza vaccines. JAMA. 1970;211(10):1672-6.
12. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis. 2009;199(2):159-67.
13. Herrera GA, Iwane MK, Cortese M, Brown C, Gershman K, Shupe A, et al. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, united states, 2003-2004. Vaccine. 2007;25(1):154-60.
14. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284(13):1655-63.
15. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006;355(24):2513-22.
16. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics. 2005;116(1):153-9.
17. Shuler CM, Iwamoto M, Bridges CB, Marin M, Neeman R, Gargiullo P, et al. Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004. Pediatrics. 2007;119(3):e587-95.
18. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med. 2010;7(4):e1000258.
19. Viboud C, Simonsen L. Does seasonal influenza vaccination increase the risk of illness with the 2009 A/H1N1 pandemic virus? PLoS Med. 2010;7(4):e1000259.
20. Jennings LC. Influenza A(H1N1)09: another public health risk to New Zealand. NZMJ. 2009;122(1298):11-6. N Z Med J. 2009 Jul 3;122(1298):11-6.
21. CDC protocol of real time RTPCR for influenza A(H1N1). Geneva: World Health Organization; 28 April 2009. Available from: http://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf
22. White P, Gunston J, Salmond C, Atkinson J, Crampton P. Atlas of Socioeconomic Deprivation in New Zealand NZDep2006. Wellington: Ministry of Health. Public Health Intelligence Occasional Bulletin No. 50, 2008.
23. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375(9720):1100-8.
24. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, et al. Clinical aspects of pandemic 2009 influenza A(H1N1) virus infection. N Engl J Med. 2010;362(18):1708-19.
25. Gerrard J, Keijzers G, Zhang P, Vossen C, Macbeth D. Clinical diagnostic criteria for isolating patients admitted to hospital with suspected pandemic influenza. Lancet. 2009;374(9702):1673.
26. ANZIC Influenza Investigators, Webb SA, Pettilä V, Seppelt I, Bellomo R, Bailey M, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009;361(20):1925-34.
27. Janjua NZ, Skowronski DM, Hottes TS, De Serres G, Crowcroft NS, Rosella LC. Seasonal vaccine and H1N1. Selection bias explains seasonal vaccine's protection. BMJ. 2009;339:b4972.
28. Garcia-Garcia L, Valdespino-Gomez JL. Seasonal vaccine and H1N1 - Authors' reply. BMJ. 2009;339:b4978.
29. Janjua NZ, Skowronski DM, Hottes TS, De Serres G, Crowcroft NS, Rosella LC. Seasonal vaccine effectiveness against pandemic A/H1N1. Lancet. 2010;375(9717):801-2.
30. Echevarría-Zuno S, Mejía-Aranguré JM, Grajales-Muñiz C, Gonzalez-Bonilla C, Borja-Aburto VH. Seasonal vaccine effectiveness against pandemic A/H1N1 - Authors' reply. Lancet. 2010;375(9717):802-3.
31. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, et al. Estimating vaccine effectiveness against laboratoryconfirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine. 2007;25(15):2842-51.
32. Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis. 2009;199(2):168-79.
33. Crum-Cianflone NF, Blair PJ, Faix D, Arnold J, Echols S, Sherman SS, et al. Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin Infect Dis. 2009;49(12):1801-10.
34. Kelly H, Barry S, Laurie K, Mercer G. Seasonal influenza vaccination and the risk of infection with pandemic influenza: a possible illustration of non-specific temporary immunity following infections. Euro Surveill. 2010;15(47):pii=19722. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?Articleld=19722.